URMC Conducting Trial for Potential Coronavirus Vaccine

Sep 8, 2020 | Clinical Trials, Coronavirus, COVID-19, News, University of Rochester Medical Center, Vaccine

URMC Conducting Trial for Potential Coronavirus Vaccine

The University of Rochester Medical Center is conducting another Phase 3 clinical trial for a potential coronavirus vaccine under the federal Operation Warp Speed initiative. More than 30,000 people from around the country will be recruited for the study, including 1,000 in Rochester. Volunteers will receive the first doses of the vaccine, which was developed by AstraZeneca and the University of Oxford.

Dr. Angela Branche, co-director of the URMC Vaccine and Treatment Evaluation Unit, said they don’t know what they’re going to find, but that’s why phase 3 trials are conducted. Phase 3 is the final stage of development of a vaccine before FDA approval. 

“We’re very optimistic about a positive outcome,” said Dr. Ann Falsey, who is co-leading the trial locally and co-directs the URMC Vaccine and Treatment Evaluation Unit.

Study Aim

According to URMC, earlier clinical trials suggest the vaccine is safe and causes an immune response to the virus. The study aims to determine whether it provides protection from infection across age groups and medical conditions.

Falsey said this is the third major Phase 3 study moving ahead in the U.S. Just last month, 1,000 volunteers from Rochester were the first to participate in another Phase 3 study for another vaccine.

Branche says federal and state officials are preparing for the possibility that one of the studies that started this summer or early fall will be able to show overwhelming efficacy. “It’s possible that it can happen in the late fall, and it’s possible it can happen before the end of the year, and it’s possible we may have to wait until early next year,” Branche said.

Lead Research/Investigator

Ann Falsey, M.D. Professor – Department of Medicine, Infectious Diseases (SMD)

Call to Action: Those interested in taking part in the study can go to covidresearch.urmc.edu or call 585-276-5212.

Source: WXXI News